United Intangible Assets vs Common Stock Total Equity Analysis
UTHR Stock | USD 287.59 5.73 2.03% |
United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Intangible Assets and its Common Stock Total Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Intangible Assets vs Common Stock Total Equity
Intangible Assets vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Intangible Assets account and Common Stock Total Equity. At this time, the significance of the direction appears to have weak relationship.
The correlation between United Therapeutics' Intangible Assets and Common Stock Total Equity is 0.32. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Intangible Assets and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of United Therapeutics are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Intangible Assets i.e., United Therapeutics' Intangible Assets and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.As of 06/14/2024, Enterprise Value is likely to grow to about 11.8 B, while Selling General Administrative is likely to drop slightly above 207.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.8B | 2.1B | 2.2B | Total Revenue | 1.7B | 1.9B | 2.3B | 2.4B |
United Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Other Current Liab | 39.6M | 319.2M | 301.6M | 339.1M | 71M | 116.3M | |
Total Current Liabilities | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 844.6M | |
Total Stockholder Equity | 2.8B | 3.4B | 4.0B | 4.8B | 6.0B | 6.3B | |
Property Plant And Equipment Net | 738.5M | 731.6M | 780.9M | 861.5M | 1.0B | 1.1B | |
Net Debt | 111.6M | 61.3M | (94.8M) | (161.2M) | (507.7M) | (482.3M) | |
Retained Earnings | 3.3B | 3.8B | 4.3B | 5.0B | 6.0B | 6.3B | |
Accounts Payable | 23.1M | 9.9M | 4.1M | 3.8M | 5.6M | 10.2M | |
Cash | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
Non Current Assets Total | 2.0B | 2.4B | 2.8B | 2.7B | 3.6B | 3.8B | |
Non Currrent Assets Other | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 91.5M | |
Cash And Short Term Investments | 2.3B | 3.0B | 3.6B | 4.2B | 3.0B | 3.1B | |
Net Receivables | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 292.8M | |
Common Stock Shares Outstanding | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 50.7M | |
Liabilities And Stockholders Equity | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Non Current Liabilities Total | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 269.4M | |
Other Current Assets | 133.8M | 88.3M | 100.4M | 219.2M | 166.2M | 174.5M | |
Other Stockholder Equity | (531.3M) | (430.5M) | (333.8M) | (190.8M) | (30.2M) | (28.7M) | |
Total Liab | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | |
Total Current Assets | 1.9B | 2.2B | 2.3B | 3.4B | 3.6B | 3.7B | |
Short Term Investments | 747.5M | 1.1B | 1.0B | 1.9B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 738.5M | 731M | 1.1B | 1.2B | 1.5B | 1.5B | |
Intangible Assets | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 84.5M | |
Other Liab | 67M | 79.4M | 104.8M | 76.8M | 88.3M | 60.5M | |
Other Assets | 293.8M | 1.6B | 370.1M | 413.5M | 475.5M | 284.7M | |
Inventory | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 55.9M | |
Property Plant Equipment | 738.5M | 731.6M | 780.9M | 861.5M | 990.7M | 1.0B | |
Net Tangible Assets | 2.6B | 3.2B | 3.9B | 4.8B | 5.5B | 5.7B | |
Retained Earnings Total Equity | 3.3B | 3.8B | 4.3B | 5.0B | 5.8B | 6.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.